查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球膿毒症診斷市場-市場機會分析和行業預測：產品、技術、方法、用途、病原體（2020-2030 年）
市場調查報告書
商品編碼
1097666

全球膿毒症診斷市場-市場機會分析和行業預測：產品、技術、方法、用途、病原體（2020-2030 年）

Global Sepsis Diagnostic Market By Product, By Technology, By Method, By Usability, By Pathogen : Global Opportunity Analysis and Industry Forecast, 2020-2030
出版日期: | 出版商: Allied Market Research | 英文 205 Pages | 商品交期: 2-3個工作天內

價格

2020年全球膿毒症診斷市場規模將達到5.6949億美元，2021-2030年復合年增長率為7.8%，到2030年達到12.75億美元。預計。

市場受到政府對膿毒症相關研究活動和傳染病流行的資助增加的推動。此外，膿毒症負擔的增加和世界老年人口的增長正在推動市場增長。然而，自動化診斷設備的高成本預計將阻礙市場增長。同時，用於早期診斷敗血症的快速診斷/即時診斷技術的發展有望在預測區間內提供市場機會。

本報告調查和分析全球膿毒症診斷市場，並提供市場概況、細分/區域市場分析、競爭形勢和主要公司概況等資訊。

目錄

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要調查結果
    • 主要投資領域
  • 波特五力分析
  • 各大公司的定位
  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
  • 分析 COVID-19 對市場的影響

第 4 章全球膿毒症診斷市場：按產品

  • 概覽
    • 市場規模和預測
  • 血液培養基
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 設備
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 檢測試劑盒/試劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 軟件
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區

第 5 章全球膿毒症診斷市場：按技術

  • 概覽
    • 市場規模和預測
  • 微生物學
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 分子診斷
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 免疫學檢查
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 流式細胞儀
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區

第 6 章全球膿毒症診斷市場：按方法

  • 概覽
    • 市場規模和預測
  • 常規診斷
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 自動診斷
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區

第 7 章全球膿毒症診斷市場：按用途

  • 概覽
    • 市場規模和預測
  • 臨床檢查
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 護理點檢查
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區

第 8 章全球膿毒症診斷市場：按病原體

  • 概覽
    • 市場規模和預測
  • 細菌性敗血症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 真菌性敗血症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區

第 9 章全球膿毒症診斷市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按產品分類
    • 北美市場規模和預測：按技術分類
    • 北美市場規模和預測：按方法分類
    • 北美市場規模和預測：按用途分類
    • 北美市場規模和預測：按病原體
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按產品分類
    • 歐洲市場規模和預測：按技術分類
    • 歐洲市場規模和預測：按方法分類
    • 歐洲市場規模和預測：按用途分類
    • 歐洲市場規模和預測：按病原體
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 義大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和預測：按產品分類
    • 亞太市場規模和預測：按技術分類
    • 亞太市場規模和預測：按方法分類
    • 亞太市場規模和預測：按用途分類
    • 亞太市場規模和預測：按病原體
    • 亞太市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 拉丁美洲/中東/非洲市場規模和預測：按產品分類
    • 拉丁美洲/中東/非洲市場規模和預測：按技術分類
    • 拉丁美洲/中東/非洲市場規模和預測：按方法分類
    • 拉丁美洲/中東/非洲市場規模和預測：按用途分類
    • 拉丁美洲/中東/非洲市場規模和預測：按病原體
    • 拉丁美洲/中東/非洲市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他拉丁美洲/中東/非洲

第 10 章公司情況

  • 簡介
  • 主要成功策略
  • 10大公司產品圖
  • 競爭性儀表板
  • 競爭熱圖
  • 主要發展

第 11 章公司簡介

    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • BioMerieux SA
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • Thermo Fisher Scientific Inc.
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • Abbott Laboratories, Inc.
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • Becton, Dickinson and Company
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • Broker Corporation
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • Beckman Coulter, Inc.
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • T2 Biosystems, Inc
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • Nanosphere, Inc.
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • Hoffmann-LA Roche Ltd
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
  • Danaher Corporation
    • 公司簡介
    • 公司快照
    • 業務部門管理
    • 產品組合
    • 成就
    • 重要的戰略動向和發展
Product Code: A03908

The global sepsis diagnostic market valued at $569.49 million in 2020, and is estimated to reach $1207.58 million by 2030, growing at a CAGR of 7.8% from 2021 to 2030.

Sepsis is a life-threatening sickness that results from your body's immune system's response to an infection. Sepsis occurs when an existing infection causes the body's immune system to overreact. When an individual is sick, his/her immune system fights the infection by releasing proteins and other substances. When this response goes awry, it causes inflammation, which leads to sepsis. Bacterial infections are the most common cause of sepsis. Septic shock, a medical emergency, can result from severe sepsis. Septic shock is characterized by a fast drop in blood pressure, organ failure, and extensive tissue destruction. It can be lethal if left untreated.

The major factors that drive the growth of the global sepsis diagnostic market include increase in government funding for sepsis-related research activities and rise in prevalence of infectious diseases. In addition, increase in burden of sepsis and rise in global geriatric population propel the market growth. However, high cost of automated diagnostics devices is expected to impede the market growth. Conversely, development of rapid diagnosis/point-of-care techniques for early sepsis diagnostics is anticipated to provide lucrative opportunities to market players during the forecast period.The global sepsis diagnostic market is segmented into product type, technology, method, usability, pathogen, and region. According to product type, the market is categorized into blood culture media, instruments, assay kits & reagents, and software. By technology, it is segregated into microbiology, molecular diagnostics,immunoassays, and flow cytometry. On the basis of method, the market is categorized into conventional diagnostics and automated diagnostics. By usability, the market is bifurcated into laboratory testing and point-of-care testing. Depending on pathogen, the market is segregated into bacterial sepsis, fungal sepsis, and other pathogen. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA

The major companies profiled in the report include: Abbott Laboratories, Inc., Becton, Dickinson and Company, Bruker Corporation, BioMerieux, Beckman Coulter, Inc., Danaher Corporation, Nanosphere, Inc., Hoffmann-LA Roche Ltd., T2 Biosystems Inc., Thermo Fisher Scientific Inc.

Key Market Segments

By Method

  • Conventional Diagnostics
  • Automated Diagnostics

By Product

  • Blood Culture Media
  • Instruments
  • Assay kits Reagents
  • Software

By Technology

  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry

By Usability

  • Laboratory Testing
  • Point-of-care Testing

By Pathogen

  • Bacterial Sepsis
  • Fungal Sepsis
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • BioMerieux SA
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories, Inc.
    • Becton, Dickinson and Company
    • Bruker Corporation
    • Beckman Coulter, Inc.
    • T2 Biosystems, Inc
    • Nanosphere, Inc.
    • Hoffmann-LA Roche Ltd
    • Danaher Corporation

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Blood Culture Media
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Instruments
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Assay kits & Reagents
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Software
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Microbiology
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Molecular Diagnostics
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Immunoassays
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Flow Cytometry
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country

CHAPTER 6: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Conventional Diagnostics
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Automated Diagnostics
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country

CHAPTER 7: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Laboratory Testing
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market analysis by country
  • 7.3 Point-of-care Testing
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market analysis by country

CHAPTER 8: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 Bacterial Sepsis
    • 8.2.1 Key market trends, growth factors and opportunities
    • 8.2.2 Market size and forecast, by region
    • 8.2.3 Market analysis by country
  • 8.3 Fungal Sepsis
    • 8.3.1 Key market trends, growth factors and opportunities
    • 8.3.2 Market size and forecast, by region
    • 8.3.3 Market analysis by country
  • 8.4 Others
    • 8.4.1 Key market trends, growth factors and opportunities
    • 8.4.2 Market size and forecast, by region
    • 8.4.3 Market analysis by country

CHAPTER 9: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION

  • 9.1 Overview
    • 9.1.1 Market size and forecast
  • 9.2 North America
    • 9.2.1 Key trends and opportunities
    • 9.2.2 North America Market size and forecast, by Product
    • 9.2.3 North America Market size and forecast, by Technology
    • 9.2.4 North America Market size and forecast, by Method
    • 9.2.5 North America Market size and forecast, by Usability
    • 9.2.6 North America Market size and forecast, by Pathogen
    • 9.2.7 North America Market size and forecast, by country
      • 9.2.7.1 U.S.
      • 9.2.7.1.1 Market size and forecast, by Product
      • 9.2.7.1.2 Market size and forecast, by Technology
      • 9.2.7.1.3 Market size and forecast, by Method
      • 9.2.7.1.4 Market size and forecast, by Usability
      • 9.2.7.1.5 Market size and forecast, by Pathogen
      • 9.2.7.2 Canada
      • 9.2.7.2.1 Market size and forecast, by Product
      • 9.2.7.2.2 Market size and forecast, by Technology
      • 9.2.7.2.3 Market size and forecast, by Method
      • 9.2.7.2.4 Market size and forecast, by Usability
      • 9.2.7.2.5 Market size and forecast, by Pathogen
      • 9.2.7.3 Mexico
      • 9.2.7.3.1 Market size and forecast, by Product
      • 9.2.7.3.2 Market size and forecast, by Technology
      • 9.2.7.3.3 Market size and forecast, by Method
      • 9.2.7.3.4 Market size and forecast, by Usability
      • 9.2.7.3.5 Market size and forecast, by Pathogen
  • 9.3 Europe
    • 9.3.1 Key trends and opportunities
    • 9.3.2 Europe Market size and forecast, by Product
    • 9.3.3 Europe Market size and forecast, by Technology
    • 9.3.4 Europe Market size and forecast, by Method
    • 9.3.5 Europe Market size and forecast, by Usability
    • 9.3.6 Europe Market size and forecast, by Pathogen
    • 9.3.7 Europe Market size and forecast, by country
      • 9.3.7.1 Germany
      • 9.3.7.1.1 Market size and forecast, by Product
      • 9.3.7.1.2 Market size and forecast, by Technology
      • 9.3.7.1.3 Market size and forecast, by Method
      • 9.3.7.1.4 Market size and forecast, by Usability
      • 9.3.7.1.5 Market size and forecast, by Pathogen
      • 9.3.7.2 France
      • 9.3.7.2.1 Market size and forecast, by Product
      • 9.3.7.2.2 Market size and forecast, by Technology
      • 9.3.7.2.3 Market size and forecast, by Method
      • 9.3.7.2.4 Market size and forecast, by Usability
      • 9.3.7.2.5 Market size and forecast, by Pathogen
      • 9.3.7.3 U.K.
      • 9.3.7.3.1 Market size and forecast, by Product
      • 9.3.7.3.2 Market size and forecast, by Technology
      • 9.3.7.3.3 Market size and forecast, by Method
      • 9.3.7.3.4 Market size and forecast, by Usability
      • 9.3.7.3.5 Market size and forecast, by Pathogen
      • 9.3.7.4 Italy
      • 9.3.7.4.1 Market size and forecast, by Product
      • 9.3.7.4.2 Market size and forecast, by Technology
      • 9.3.7.4.3 Market size and forecast, by Method
      • 9.3.7.4.4 Market size and forecast, by Usability
      • 9.3.7.4.5 Market size and forecast, by Pathogen
      • 9.3.7.5 Spain
      • 9.3.7.5.1 Market size and forecast, by Product
      • 9.3.7.5.2 Market size and forecast, by Technology
      • 9.3.7.5.3 Market size and forecast, by Method
      • 9.3.7.5.4 Market size and forecast, by Usability
      • 9.3.7.5.5 Market size and forecast, by Pathogen
      • 9.3.7.6 Rest of Europe
      • 9.3.7.6.1 Market size and forecast, by Product
      • 9.3.7.6.2 Market size and forecast, by Technology
      • 9.3.7.6.3 Market size and forecast, by Method
      • 9.3.7.6.4 Market size and forecast, by Usability
      • 9.3.7.6.5 Market size and forecast, by Pathogen
  • 9.4 Asia-Pacific
    • 9.4.1 Key trends and opportunities
    • 9.4.2 Asia-Pacific Market size and forecast, by Product
    • 9.4.3 Asia-Pacific Market size and forecast, by Technology
    • 9.4.4 Asia-Pacific Market size and forecast, by Method
    • 9.4.5 Asia-Pacific Market size and forecast, by Usability
    • 9.4.6 Asia-Pacific Market size and forecast, by Pathogen
    • 9.4.7 Asia-Pacific Market size and forecast, by country
      • 9.4.7.1 Japan
      • 9.4.7.1.1 Market size and forecast, by Product
      • 9.4.7.1.2 Market size and forecast, by Technology
      • 9.4.7.1.3 Market size and forecast, by Method
      • 9.4.7.1.4 Market size and forecast, by Usability
      • 9.4.7.1.5 Market size and forecast, by Pathogen
      • 9.4.7.2 China
      • 9.4.7.2.1 Market size and forecast, by Product
      • 9.4.7.2.2 Market size and forecast, by Technology
      • 9.4.7.2.3 Market size and forecast, by Method
      • 9.4.7.2.4 Market size and forecast, by Usability
      • 9.4.7.2.5 Market size and forecast, by Pathogen
      • 9.4.7.3 Australia
      • 9.4.7.3.1 Market size and forecast, by Product
      • 9.4.7.3.2 Market size and forecast, by Technology
      • 9.4.7.3.3 Market size and forecast, by Method
      • 9.4.7.3.4 Market size and forecast, by Usability
      • 9.4.7.3.5 Market size and forecast, by Pathogen
      • 9.4.7.4 India
      • 9.4.7.4.1 Market size and forecast, by Product
      • 9.4.7.4.2 Market size and forecast, by Technology
      • 9.4.7.4.3 Market size and forecast, by Method
      • 9.4.7.4.4 Market size and forecast, by Usability
      • 9.4.7.4.5 Market size and forecast, by Pathogen
      • 9.4.7.5 South Korea
      • 9.4.7.5.1 Market size and forecast, by Product
      • 9.4.7.5.2 Market size and forecast, by Technology
      • 9.4.7.5.3 Market size and forecast, by Method
      • 9.4.7.5.4 Market size and forecast, by Usability
      • 9.4.7.5.5 Market size and forecast, by Pathogen
      • 9.4.7.6 Rest of Asia-Pacific
      • 9.4.7.6.1 Market size and forecast, by Product
      • 9.4.7.6.2 Market size and forecast, by Technology
      • 9.4.7.6.3 Market size and forecast, by Method
      • 9.4.7.6.4 Market size and forecast, by Usability
      • 9.4.7.6.5 Market size and forecast, by Pathogen
  • 9.5 LAMEA
    • 9.5.1 Key trends and opportunities
    • 9.5.2 LAMEA Market size and forecast, by Product
    • 9.5.3 LAMEA Market size and forecast, by Technology
    • 9.5.4 LAMEA Market size and forecast, by Method
    • 9.5.5 LAMEA Market size and forecast, by Usability
    • 9.5.6 LAMEA Market size and forecast, by Pathogen
    • 9.5.7 LAMEA Market size and forecast, by country
      • 9.5.7.1 Brazil
      • 9.5.7.1.1 Market size and forecast, by Product
      • 9.5.7.1.2 Market size and forecast, by Technology
      • 9.5.7.1.3 Market size and forecast, by Method
      • 9.5.7.1.4 Market size and forecast, by Usability
      • 9.5.7.1.5 Market size and forecast, by Pathogen
      • 9.5.7.2 Saudi Arabia
      • 9.5.7.2.1 Market size and forecast, by Product
      • 9.5.7.2.2 Market size and forecast, by Technology
      • 9.5.7.2.3 Market size and forecast, by Method
      • 9.5.7.2.4 Market size and forecast, by Usability
      • 9.5.7.2.5 Market size and forecast, by Pathogen
      • 9.5.7.3 South Africa
      • 9.5.7.3.1 Market size and forecast, by Product
      • 9.5.7.3.2 Market size and forecast, by Technology
      • 9.5.7.3.3 Market size and forecast, by Method
      • 9.5.7.3.4 Market size and forecast, by Usability
      • 9.5.7.3.5 Market size and forecast, by Pathogen
      • 9.5.7.4 Rest of LAMEA
      • 9.5.7.4.1 Market size and forecast, by Product
      • 9.5.7.4.2 Market size and forecast, by Technology
      • 9.5.7.4.3 Market size and forecast, by Method
      • 9.5.7.4.4 Market size and forecast, by Usability
      • 9.5.7.4.5 Market size and forecast, by Pathogen

CHAPTER 10: COMPANY LANDSCAPE

  • 10.1. Introduction
  • 10.2. Top winning strategies
  • 10.3. Product Mapping of Top 10 Player
  • 10.4. Competitive Dashboard
  • 10.5. Competitive Heatmap
  • 10.6. Key developments

CHAPTER 11: COMPANY PROFILES

11.1

    • 11.1.1 Company overview
    • 11.1.2 Company snapshot
    • 11.1.3 Operating business segments
    • 11.1.4 Product portfolio
    • 11.1.5 Business performance
    • 11.1.6 Key strategic moves and developments
  • 11.2 BioMerieux SA
    • 11.2.1 Company overview
    • 11.2.2 Company snapshot
    • 11.2.3 Operating business segments
    • 11.2.4 Product portfolio
    • 11.2.5 Business performance
    • 11.2.6 Key strategic moves and developments
  • 11.3 Thermo Fisher Scientific Inc.
    • 11.3.1 Company overview
    • 11.3.2 Company snapshot
    • 11.3.3 Operating business segments
    • 11.3.4 Product portfolio
    • 11.3.5 Business performance
    • 11.3.6 Key strategic moves and developments
  • 11.4 Abbott Laboratories, Inc.
    • 11.4.1 Company overview
    • 11.4.2 Company snapshot
    • 11.4.3 Operating business segments
    • 11.4.4 Product portfolio
    • 11.4.5 Business performance
    • 11.4.6 Key strategic moves and developments
  • 11.5 Becton, Dickinson and Company
    • 11.5.1 Company overview
    • 11.5.2 Company snapshot
    • 11.5.3 Operating business segments
    • 11.5.4 Product portfolio
    • 11.5.5 Business performance
    • 11.5.6 Key strategic moves and developments
  • 11.6 Bruker Corporation
    • 11.6.1 Company overview
    • 11.6.2 Company snapshot
    • 11.6.3 Operating business segments
    • 11.6.4 Product portfolio
    • 11.6.5 Business performance
    • 11.6.6 Key strategic moves and developments
  • 11.7 Beckman Coulter, Inc.
    • 11.7.1 Company overview
    • 11.7.2 Company snapshot
    • 11.7.3 Operating business segments
    • 11.7.4 Product portfolio
    • 11.7.5 Business performance
    • 11.7.6 Key strategic moves and developments
  • 11.8 T2 Biosystems, Inc
    • 11.8.1 Company overview
    • 11.8.2 Company snapshot
    • 11.8.3 Operating business segments
    • 11.8.4 Product portfolio
    • 11.8.5 Business performance
    • 11.8.6 Key strategic moves and developments
  • 11.9 Nanosphere, Inc.
    • 11.9.1 Company overview
    • 11.9.2 Company snapshot
    • 11.9.3 Operating business segments
    • 11.9.4 Product portfolio
    • 11.9.5 Business performance
    • 11.9.6 Key strategic moves and developments
  • 11.10 Hoffmann-LA Roche Ltd
    • 11.10.1 Company overview
    • 11.10.2 Company snapshot
    • 11.10.3 Operating business segments
    • 11.10.4 Product portfolio
    • 11.10.5 Business performance
    • 11.10.6 Key strategic moves and developments
  • 11.11 Danaher Corporation
    • 11.11.1 Company overview
    • 11.11.2 Company snapshot
    • 11.11.3 Operating business segments
    • 11.11.4 Product portfolio
    • 11.11.5 Business performance
    • 11.11.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 2. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR BLOOD CULTURE MEDIA, BY REGION , 2020-2030,($MILLION)
  • TABLE 3. GLOBAL SEPSIS DIAGNOSTIC MARKET BLOOD CULTURE MEDIA BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 4. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR INSTRUMENTS, BY REGION , 2020-2030,($MILLION)
  • TABLE 5. GLOBAL SEPSIS DIAGNOSTIC MARKET INSTRUMENTS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 6. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR ASSAY KITS & REAGENTS, BY REGION , 2020-2030,($MILLION)
  • TABLE 7. GLOBAL SEPSIS DIAGNOSTIC MARKET ASSAY KITS & REAGENTS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 8. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR SOFTWARE, BY REGION , 2020-2030,($MILLION)
  • TABLE 9. GLOBAL SEPSIS DIAGNOSTIC MARKET SOFTWARE BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 10. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
  • TABLE 11. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR MICROBIOLOGY, BY REGION , 2020-2030,($MILLION)
  • TABLE 12. GLOBAL SEPSIS DIAGNOSTIC MARKET MICROBIOLOGY BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 13. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR MOLECULAR DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
  • TABLE 14. GLOBAL SEPSIS DIAGNOSTIC MARKET MOLECULAR DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 15. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR IMMUNOASSAYS, BY REGION , 2020-2030,($MILLION)
  • TABLE 16. GLOBAL SEPSIS DIAGNOSTIC MARKET IMMUNOASSAYS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 17. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR FLOW CYTOMETRY, BY REGION , 2020-2030,($MILLION)
  • TABLE 18. GLOBAL SEPSIS DIAGNOSTIC MARKET FLOW CYTOMETRY BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 19. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
  • TABLE 20. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR CONVENTIONAL DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
  • TABLE 21. GLOBAL SEPSIS DIAGNOSTIC MARKET CONVENTIONAL DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 22. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR AUTOMATED DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
  • TABLE 23. GLOBAL SEPSIS DIAGNOSTIC MARKET AUTOMATED DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 24. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
  • TABLE 25. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR LABORATORY TESTING, BY REGION , 2020-2030,($MILLION)
  • TABLE 26. GLOBAL SEPSIS DIAGNOSTIC MARKET LABORATORY TESTING BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 27. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR POINT-OF-CARE TESTING, BY REGION , 2020-2030,($MILLION)
  • TABLE 28. GLOBAL SEPSIS DIAGNOSTIC MARKET POINT-OF-CARE TESTING BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 29. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
  • TABLE 30. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR BACTERIAL SEPSIS, BY REGION , 2020-2030,($MILLION)
  • TABLE 31. GLOBAL SEPSIS DIAGNOSTIC MARKET BACTERIAL SEPSIS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 32. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR FUNGAL SEPSIS, BY REGION , 2020-2030,($MILLION)
  • TABLE 33. GLOBAL SEPSIS DIAGNOSTIC MARKET FUNGAL SEPSIS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 34. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
  • TABLE 35. GLOBAL SEPSIS DIAGNOSTIC MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 36. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION, 2020-2030,($MILLION)
  • TABLE 37. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 38. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
  • TABLE 39. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
  • TABLE 40. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
  • TABLE 41. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
  • TABLE 42. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 43. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 44. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 45. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 46. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 47. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 48. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 49. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 50. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 51. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 52. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 53. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 54. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 55. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 56. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 57. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 58. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 59. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
  • TABLE 60. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
  • TABLE 61. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
  • TABLE 62. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
  • TABLE 63. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 64. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 65. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 66. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 67. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 68. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 69. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 70. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 71. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 72. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 73. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 74. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 75. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 76. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 77. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 78. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 79. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 80. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 81. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 82. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 83. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 84. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 85. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 86. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 87. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 88. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 89. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 90. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 91. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 92. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 93. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 94. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 95. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
  • TABLE 96. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
  • TABLE 97. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
  • TABLE 98. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
  • TABLE 99. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 100. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 101. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 102. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 103. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 104. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 105. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 106. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 107. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 108. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 109. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 110. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 111. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 112. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 113. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 114. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 115. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 116. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 117. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 118. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 119. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 120. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 121. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 122. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 123. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 124. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 125. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 126. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 127. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 128. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 129. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 130. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 131. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
  • TABLE 132. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
  • TABLE 133. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
  • TABLE 134. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
  • TABLE 135. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 136. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 137. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 138. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 139. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 140. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 141. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 142. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 143. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 144. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 145. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 146. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 147. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 148. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 149. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 150. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 151. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 152. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
  • TABLE 153. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
  • TABLE 154. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
  • TABLE 155. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
  • TABLE 156.: COMPANY SNAPSHOT
  • TABLE 157.: OPERATING SEGMENTS
  • TABLE 158.: PRODUCT PORTFOLIO
  • TABLE 159.: NET SALES,
  • TABLE 160.: KEY STRATERGIES
  • TABLE 161.BIOMERIEUX SA: COMPANY SNAPSHOT
  • TABLE 162.BIOMERIEUX SA: OPERATING SEGMENTS
  • TABLE 163.BIOMERIEUX SA: PRODUCT PORTFOLIO
  • TABLE 164.BIOMERIEUX SA: NET SALES,
  • TABLE 165.BIOMERIEUX SA: KEY STRATERGIES
  • TABLE 166.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 167.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 168.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 169.THERMO FISHER SCIENTIFIC INC.: NET SALES,
  • TABLE 170.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
  • TABLE 171.ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 172.ABBOTT LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 173.ABBOTT LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 174.ABBOTT LABORATORIES, INC.: NET SALES,
  • TABLE 175.ABBOTT LABORATORIES, INC.: KEY STRATERGIES
  • TABLE 176.BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 177.BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS
  • TABLE 178.BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 179.BECTON, DICKINSON AND COMPANY: NET SALES,
  • TABLE 180.BECTON, DICKINSON AND COMPANY: KEY STRATERGIES
  • TABLE 181.BRUKER CORPORATION: COMPANY SNAPSHOT
  • TABLE 182.BRUKER CORPORATION: OPERATING SEGMENTS
  • TABLE 183.BRUKER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 184.BRUKER CORPORATION: NET SALES,
  • TABLE 185.BRUKER CORPORATION: KEY STRATERGIES
  • TABLE 186.BECKMAN COULTER, INC.: COMPANY SNAPSHOT
  • TABLE 187.BECKMAN COULTER, INC.: OPERATING SEGMENTS
  • TABLE 188.BECKMAN COULTER, INC.: PRODUCT PORTFOLIO
  • TABLE 189.BECKMAN COULTER, INC.: NET SALES,
  • TABLE 190.BECKMAN COULTER, INC.: KEY STRATERGIES
  • TABLE 191.T2 BIOSYSTEMS, INC: COMPANY SNAPSHOT
  • TABLE 192.T2 BIOSYSTEMS, INC: OPERATING SEGMENTS
  • TABLE 193.T2 BIOSYSTEMS, INC: PRODUCT PORTFOLIO
  • TABLE 194.T2 BIOSYSTEMS, INC: NET SALES,
  • TABLE 195.T2 BIOSYSTEMS, INC: KEY STRATERGIES
  • TABLE 196.NANOSPHERE, INC.: COMPANY SNAPSHOT
  • TABLE 197.NANOSPHERE, INC.: OPERATING SEGMENTS
  • TABLE 198.NANOSPHERE, INC.: PRODUCT PORTFOLIO
  • TABLE 199.NANOSPHERE, INC.: NET SALES,
  • TABLE 200.NANOSPHERE, INC.: KEY STRATERGIES
  • TABLE 201.HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 202.HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 203.HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 204.HOFFMANN-LA ROCHE LTD: NET SALES,
  • TABLE 205.HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
  • TABLE 206.DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 207.DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 208.DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 209.DANAHER CORPORATION: NET SALES,
  • TABLE 210.DANAHER CORPORATION: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.GLOBAL SEPSIS DIAGNOSTIC MARKET SEGMENTATION
  • FIGURE 2.GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030
  • FIGURE 3.GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.GLOBAL SEPSIS DIAGNOSTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY PRODUCT,2020(%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF BLOOD CULTURE MEDIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INSTRUMENTS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ASSAY KITS & REAGENTS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF SOFTWARE GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 16.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY TECHNOLOGY,2020(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MICROBIOLOGY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MOLECULAR DIAGNOSTICS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF IMMUNOASSAYS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF FLOW CYTOMETRY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 21.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY METHOD,2020(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CONVENTIONAL DIAGNOSTICS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF AUTOMATED DIAGNOSTICS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 24.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY USABILITY,2020(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF LABORATORY TESTING GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF POINT-OF-CARE TESTING GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 27.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY PATHOGEN,2020(%)
  • FIGURE 28.COMPARATIVE SHARE ANALYSIS OF BACTERIAL SEPSIS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF FUNGAL SEPSIS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHERS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
  • FIGURE 31.GLOBAL SEPSIS DIAGNOSTIC MARKET BY REGION,2020
  • FIGURE 32.U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 33.CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 34.MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 35.GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 36.FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 37.U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 38.ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 39.SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 40.REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 41.JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 42.CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 43.AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 44.INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 45.SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 46.REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 47.BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 48.SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 49.SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 50.REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
  • FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 55.COMPETITIVE DASHBOARD
  • FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 57..: NET SALES ,($MILLION)
  • FIGURE 58.BIOMERIEUX SA.: NET SALES ,($MILLION)
  • FIGURE 59.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
  • FIGURE 60.ABBOTT LABORATORIES, INC..: NET SALES ,($MILLION)
  • FIGURE 61.BECTON, DICKINSON AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 62.BRUKER CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 63.BECKMAN COULTER, INC..: NET SALES ,($MILLION)
  • FIGURE 64.T2 BIOSYSTEMS, INC.: NET SALES ,($MILLION)
  • FIGURE 65.NANOSPHERE, INC..: NET SALES ,($MILLION)
  • FIGURE 66.HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)
  • FIGURE 67.DANAHER CORPORATION.: NET SALES ,($MILLION)